NEW2026 Annual Stockholders’ Meeting – December 2, 2026|Click Here for Meeting Details and Proxy MaterialsMeeting Details & Proxy Materials
NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

77_IGC-Pharma-Secures-New-U.S.-Patent-as-Pharmaceutical-Cannabinoids-Gain-Regulatory-Momentum-
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum  
Read More →
76_-IGC-Pharma-Highlights-Strengthened-Strategic-Position-Amid-U.S.-Hemp-Regulatory-Shifts
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines 
Read More →
75_IGC-Pharma-Announces-Coverage-Report-by-Ascendiant-Capital-Markets-about-the-“Reports-Q2-results
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.”
Read More →
74_-IGC-Pharma-Reports-65%-Patient-Enrollment-Milestone-in-Phase-2-CALMA-Alzheimer’s-Agitation-Trial
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial 
Read More →
73_-IGC-Pharma-Announces-Activation-of-New-Clinical-Trial-Site
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer’s Disease
Read More →
72_IGC-Pharma-Leverages-MINT-AD-to-Identify-Socioeconomic-Risk-Factors-Driving-Alzheimer's-and-Aging-Trends-2
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends
Read More →
71_IGC-Pharma-Reports-Accelerated-Q2
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
Read More →
70_USPTO-Grants-IGC-Pharma-Patent-Rights-for-Novel-Composition-Targeting-Alzheimer’s-Disease-and-Central-Nervous-System-Disorders
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer’s Disease and Central Nervous System Disorders
Read More →
69_IGC-Pharma-to-Host-Mid-Year-Fiscal-2026-Shareholder-Update-Call-on-November-17,-2025
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
Read More →
68_IGC-Pharma-Expands-its-AI-Powered-Drug-Discovery-In-Silico-Pipeline
IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
Read More →
67_IGC-Pharma-Advances-to-Semi-Finals-in-the-Alzheimer’s-Insights-AI-Prize-with-“AHA--Agentic-Harmonization-Assistant”
IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant” 
Read More →
66_IPhase-2-CALMA-Clinical-Trial-to-University-of-South-Florida’s-
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida’s Department of Psychiatry and Behavioral Neurosciences 
Read More →
65_Results-2025
IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
Read More →
64_IGC-Pharma’s-Preclinical-Data-for-IGC-1C-
IGC Pharma’s Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer’s Disease 
Read More →
63_IGC-Pharma-Adds-Ichor-Research-as-New-Site-for-CALMA
IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer’s Trial 
Read More →
61_IGC-Pharma-Announces-New-Preclinical-Data-Demonstrating-TGR-63’s (1)
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology 
Read More →